Cephradine Pregnancy and Breastfeeding Warnings
Cephradine is also known as: Velosef
Cephradine Pregnancy Warnings
There are no case reports of adverse effects of cephradine on the fetus. Data reveal that cephradine is more likely to produce significant and therapeutic fetal levels after 15 weeks gestation. In the first and second trimesters, intravenously or orally administered cephradine produces amniotic fluid levels of 1 mcg/mL or less. A 1 gram intravenous dose between weeks 15 and 30, however, produces amniotic fluid levels ranging from 3 to 15 mcg/mL within 50 minutes of administration. The Michigan Medicaid surveillance study showed a possible association between cephradine and congenital defects. This report is a summary of information from two studies, one in which 239 of 104,000 pregnant women from 1980 to 1983, and one in which 339 of 229,000 pregnant women from 1985 to 1992 received cephradine. In the first study 20 total defects (3 cardiovascular defects) were observed (14 and 2 were expected, respectively). In the second study, 27 total defects (9 cardiovascular defects) were observed (14 and 3 were expected, respectively). Cleft palate was not observed in either study. These data support an association between cephradine and congenital defects, although other causes, such as the underlying disease(s) of the mother and concomitant drug therapy are unaccounted for.
Cephradine has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy. Cephradine should only be given during pregnancy when need has been clearly established.
Cephradine Breastfeeding Warnings
Cephradine is excreted into human milk in small amounts. Adverse effects in the nursing infant are unlikely. Other cephalosporins have been classified as compatible with breast-feeding by the American Academy of Pediatrics.
No reports of adverse effects in the nursing infant are reported. After cephradine 500 mg orally every 6 hours for 48 hours, human milk levels of 0.6 mcg/mL are reported. The average milk to maternal serum level ratio is 0.2. While this level and ratio are extremely low, some experts warn of unknown direct effects on the nursing infant, modification of neonatal bowel flora, and difficulty in the interpretation of culture results in the evaluation of a suspected infection.
- Cephradine use while Breastfeeding (in more detail)
- cephradine Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.